Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
NCT03442985 · Clementia Pharmaceuticals Inc. · PHASE2 · terminated · last registry update 2022-08-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial was terminated early to analyze the accumulated data and evaluate the efficacy, safety and future of palovarotene in MO.” | – | Registry record, Clementia Pharmaceuticals Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RARG within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-07-11Results posted on the registry: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), bomedemstat + tretinoin (NCT02842827)
- 2023-07-11Results posted on the registry: Galderma R&D, Adapalene/Benzoyl Peroxide (NCT00446043)
- 2023-06-12Results posted on the registry: Incyte Corporation, INCB059872 + all-trans retinoic acid (ATRA) (NCT02712905)
- 2023-06-07Also stopped (withdrawn): Massachusetts General Hospital, Isotretinoin (NCT02795143)
- 2023-04-13Also stopped (withdrawn): University of Louisville, Topical Adapalene Gel 0.1% (NCT04823845)
- 2023-04-06Also stopped (withdrawn): Massachusetts General Hospital, a drug against RARG (NCT03707236)
- 2023-03-14Results posted on the registry: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT03786783)
- 2023-03-14Results posted on the registry: Clementia Pharmaceuticals Inc., Palovarotene (NCT03312634)
- 2023-03-02Results posted on the registry: University of Colorado, Denver, Pembrolizumab with All-Trans Retinoic Acid (NCT03200847)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2022-12-09Results posted on the registry: Galderma R&D, Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel + Oral doxycycline hyclate (NCT02899000)
- 2022-11-08Phase 3 first posted: Icahn School of Medicine at Mount Sinai, Duobrii + Placebo (NCT05608499)
- 2022-11-04Also stopped (terminated): University of Cologne, antibody ch14.18 + GM-CSF (NCT02641782)
- 2022-11-03Also stopped (suspended): Azidus Brasil, arbutin, tretinoin, triamcinolone + Triluma (NCT00717652)
- 2022-10-10Phase 3 first posted: Jinnah Postgraduate Medical Centre, Tazarotene gel 0.1% (NCT05573425)
- 2022-09-22Phase 3 first posted: Teva Pharmaceuticals USA, Trifarotene 0.005 % Topical Cream + AKLIEF® (NCT05550337)
- 2022-09-13Phase 3 first posted: University of Oklahoma, Benzoyl peroxide + Adapalene Gel (NCT05536882)
- 2022-09-01Also stopped (withdrawn): Y-mAbs Therapeutics, Naxitamab + GM-CSF (NCT04909515)
- 2022-08-25Results posted on the registry: LEO Pharma, Isotretinoin (NCT04154293)
- 2022-08-23Also stopped (terminated): Galderma R&D, Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05% + Cetaphil® Moisturizing Cream as Inactive Control (NCT00669071)
- 2022-06-30Phase 3 first posted: Peking University People's Hospital, all-trans retinoic acid + Eltrombopag (NCT05438875)
- 2022-06-15Results posted on the registry: University Hospitals Cleveland Medical Center, Isotretinoin (NCT01560585)
- 2022-06-15Also stopped (terminated): University Hospitals Cleveland Medical Center, Isotretinoin (NCT01560585)
- 2022-05-16Results posted on the registry: Memorial Sloan Kettering Cancer Center, anti-GD2 murine IgG3 monoclonal antibody 3F8 + anti-GD2 murine IgG3 monoclonal antibody 3F8 (NCT00072358)
- 2022-05-10Results posted on the registry: Galderma R&D, Trifarotene cream + Doxycycline hyclate (NCT04451330)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision